Pharma Intelligence
Informa

Pharmaprojects
医药数据库概要及使用介绍

全球R&D新药研发信息【1980年至今】

Robert Wu
客服及产品培训专员（亚太区）
Robert.wu@informa.com
WeChat ID: Robert_wu2018

Informa
制药智库公众号

Pharma Intelligence
Informa

目录

- Informa医药智库一览
- Citeline系列一览：
  - 分析师团队 & 内容编辑流程
  - 实际应用
  - Pharmaprojects概要 - 全球临床药物信息
    - 内容涵盖范围
    - 信息引用来源
    - 药物报告内容
  - 其他模块一览（未订阅）：
    - *Trialtrove - 全球临床试验信息*
    - *Sitetrove - 全球研究者及机构信息*
    - *Citeline Engage – 美国医师及患者真实世界数据*
- 分析师咨询服务（Ask the Analyst）
- Citeline主要功能【逻辑检索、数据显示、数据追踪】
- 使用案例【1】– 综合格局分析
- 使用案例【2】– 业界动态追踪
- 客户支持：
  - 免费全球公开培训
  - 关键辅助链接

Informa

医药智库全产品 – 2020年



回到目录页面

Pharma Intelligence
Informa

Citeline系列一览

全球R&D统一数据平台

Citeline – 全球领先R&D综合数据平台（研发管线、临床试验、研究者及机构），以最全面、可靠、及时的信息进一步优化研发成本控制及产出

Citeline
Informa Pharma Intelligence

Pharmaprojects
Informa Pharma Intelligence
全面追踪全球范围内从临床前至上市的R&D管线，详细覆盖药物、公司、研发历程或监管状态等多种信息

Trialtrove
Informa Pharma Intelligence
完整掌握全球临床试验信息及综合格局，提供各种用时数据及可视化功能以便临床方案设计或可行性评估

Sitetrove
Informa Pharma Intelligence
查阅全球研究者及机构资讯，并了解其联系方式及以往临床经历，同时提供独有的"研究者分级排行"功能进一步推荐最佳潜在人选

Citeline Engage
Informa Pharma Intelligence
提供真实世界数据并进一步结合附加*Engage*服务，以便招募资深或接触全新研究人选，优化临床项目方案，或推广选定项目以提高患者募集

避免研发失败的巨大代价

考虑研发成本：
新药研发总成本约5-25亿美元…
同时伴有约98%失败率

Citeline系列将在研发各领域提供专业帮助

涵盖研发趋势、临床研究者及机构选择，以及临床项目设计等…

临床试验阶段尤其重要
【占总成本约80%】

Citeline综合智库可助您作出更经济及高效的明智决策

- 作出可行或不可行的正确决策（同时降低失败机率）
- 设计无须额外临床试验的临床项目
- 降低入组及临床试验所须用时

Citeline – 降低研发用时及成本，同时优化临床方案

- ✓ 全面了解全球研发药物及临床试验格局及竞争趋势
- ✓ 根据评估竞争对手的药物信息及临床试验方案，进一步优化研发计划及临床方案
- ✓ 通过分析临床试验项目的目标终点及临床结果，避免日后作出不必要的临床方案修订
- ✓ 通过查阅以往、当前及未来的临床试验、研发人员及机构的相关活动及研发密度等信息并提前作出可行性评估，以便选择合适的国家进行临床试验
- ✓ 数千条衡量基准均可一秒检索相关信息，以便优化临床计划及时间方案
- ✓ 识别最具资历及研发记录、并符合您研究方案的临床研究人员及机构
- ✓ 降低选择Non-Enrolling Sites的风险
- ✓ 评估相似临床方案的临床试验时间信息，以便作出更准确的预算管理及用时预测
- ✓ 准确追踪及评估竞争对手的研发药物与临床试验进展

业内最全面及准确的全球R&D综合数据库

250+
业内专家
全面追踪、分析、扩大研发数据

43,000+
信息来源
持续增加中

343,000+
临床试验完整报告
（一至四期）

84,000+
全球临床药物完整报告
（记录超35年研发历程）

478,000+
临床研究人员
（通过以往经验进行分级）

179,000+
临床研究机构
（以类型及临床经验区分）

Citeline分析师团队 – 一切均由专家而制

拥有超250名了解您需求并常驻全球主要市场的各疾病领域专家团队
一切数据均由分析师手动查证及编制

精通各大领域

一切均由专家手动查证、评估，并编制内容

丰富业界经验

累积数千年的从业及专业经验，提供值得信赖的专业见解

业内顶级分析

以全面、透明及独立的视角作出专业分析

内容编制流程

查证
创建
编制
发表
复审
更新

Pharma Intelligence
Informa

Citeline实际应用

- 临床项目管理（Clinical Operation）
- 其他领域：
  - 药物研发（Research & Development）
  - 商业拓展（Business Development & Licensing）
  - 竞争格局分析（Competitive Intelligence）
  - 法规及注册（Regulatory Affairs）
  - 医学事务（Medical Affairs）

通过Citeline数据库及附加服务，全面优化并提高临床试验项目各大环节效率



Notes:
1. “Study Conduct” may also be referred to as “Study Maintenance”

临床以外各部门亦使用Citeline实现日常工作及目标

注：= Citeline数据库 = Citeline Engage附加服务 ☆ = Sitetrove新加真实世界数据

	药物研发 Research & Development	商业拓展 Business Development & Licensing	竞争格局分析 Competitive Intelligence	法规及注册 Regulatory Affairs	医学事务 Medical Affairs
Citeline数据库或附加服务	Pharmaprojects Trialtrove	Pharmaprojects Trialtrove	Pharmaprojects Trialtrove Sitetrove ☆ Citeline Engage Gather	Pharmaprojects Trialtrove Sitetrove ☆ Citeline Engage Gather	Pharmaprojects Trialtrove Sitetrove ☆ Citeline Engage Recruit, Gather and Skoop
Citeline实际应用	根据MoA、靶点、化学结构、适应症等信息进行早期研发立项信息收集	通过公司、疾病、研发状态等全面评估全球竞争环境	通过公司、疾病、研发状态等全面评估全球药研竞争环境	查阅竞争对手监管策略	根据MoA、靶点、化学结构、适应症等信息查阅竞争格局或相似项目
	追踪创新药/NCE管线	识别潜在授权许可或合作机遇	通过公司、疾病、研发状态等全面评估全球临床竞争环境	识别进入快速审评途径的研发项目	追踪研究者或业界权威临床参与程度掌握可用患者群体 ☆
	根据竞争格局分析识别全新潜在领域或研发策略	分析关键市场事件（如：研发终止、获批上市、孤儿药状态等）	搜寻个别在研项目全球或各地研发状态	搜寻个别在研项目全球或各地研发状态	识别全新患者群体
	了解罕见病领域研发管线及格局	搜寻仍拥研发前景的"堕落天使"药物（Fallen Angel）	识别相应研发者、业界权威或机构掌握竞争资讯 ☆	识别相应研发者、业界权威或机构掌握监管资讯 ☆	向医疗从业者网络推广临床项目提高医生及患者对特定项目的认识及科学理论
		了解罕见病领域研发管线及格局	与医疗从业者或业界权威合作进一步收集竞争资讯	与医疗从业者或业界权威合作获取独家反馈	与医疗从业者或业界权威合作询问其用药趋势或患者倾向等信息

Pharma Intelligence
Informa

Pharmaprojects概要

全球R&D临床药物信息

Pharmaprojects是业界最值信赖的药物研发数据，全面追踪全球R&D管线从临床前至上市的研发或上市动态

Pharmaprojects 提供多方面支持

- 84,000+ 药物完整报告
- 5,000+ 每年新增药物
- 43,000+ 公共领域引用来源
- 17,500+ 处于研发态势的药物
- 3,800+ 作用机制
- 3,100+ 靶点
- 1,700+ 适应症
- 600+ 罕见病

内容均由分析师团队手动查证及编制，并与Trialtrove临床试验数据相互连接

商业拓展 & 识别潜在机遇

识别并评估潜在引进项目或合作机遇，搜寻仍拥有研发前景的“堕落天使”药物（Fallen Angel），执行尽职调查及详细评估等

研发竞争格局 & 监管状态

清晰并迅速地了解各地或特定领域完整竞争格局，以及个别在研项目的研发及监管状态

完整药物查询

搜寻拥有相似化学结构或特定作用机制的项目，识别拥有特定药物来源（如：生物制剂）或靶点（如：PD-L1）的药物

罕见病领域资讯

快速检索出全球当前罕见病管线及相应公司，掌握其研发地点及相应状态

引用全球公共领域内一切可用资讯 – 由分析师手动查证及编译

确保提供完整信息来源出处（如：引用日期、信息链接）

主要信息来源 – 目前引用超过43,000个信息来源（持续增长中）

- 超过70个来自各国或地区的监管或临床试验注册机构（如：FDA, EMA, ClinicalTrials.gov, EUCTR, JAPIC, ChiCTR等）
- 超过90个其他临床试验资讯来源（如：申办方注册信息、合作机构、主要医疗中心）
- 超过5000个企业信息（全面涵盖管线、新闻报道、投资者，以及其他网页）
- 所有主流医学会议或杂志
- 新闻资源、投资者演讲、美国证监会文件，以及公司年度报告等
- 各国医疗及卫生机构的官方网页
- 医学杂志及论坛
- USAN与INN lists, eMolecules, ChemSpider, & ChemIDplus
- 其他线上资源，如：Gene（前身为EntrezGene）、PubMed，以及Espacenet等

Pharmaprojects药物报告涵盖范围

完整涵盖临床前至上市信息…

全面覆盖1980年至今所有商用或处方用的全球各疾病领域药物研发信息 –
其中包括：创新药、生物制剂、疫苗、新型或重新配方药物、技术、伴随诊断等
（非处方药、仿制药、医疗器械等除外）

涵盖全球超过84,000个完整药物报告

- 研发方及合作方信息
- 所有应用适应症及全球各市场研发或上市状态
- 最高临床阶段信息
- 重大事件综述 – 全面追踪关键事件（如：研发状态变动、孤儿药申请批准或首次上市等）
- 作用机制及靶点
- 是否有合作空间?
- 药物化学信息（如：药物来源、化学名、药代动力学或化学结构等）
- 研发信息
- 临床前信息

点击查阅Pharmaprojects数据库涵盖范围说明

Pharmaprojects药物报告【例】

Drug

- Drug Summary
- Chemical data
- Activity
- Trialtrove Trials
- Disease / Company / Country
- Partnering Availability
- Event History
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

obeticholic acid

6-ECDCA; 6-ECDCA (capsule); 6-ECDCA (tablet); 6alpha-ethylchenodeoxycholic acid; DSP 1747; DSP-1747; DSP-1747 (capsule); DSP-1747 (tablet); DSP1747; INT 747; INT-747; INT-747 (capsule); INT-747 (tablet); INT747; obeticholic acid; obeticholic acid (capsule); obeticholic acid (tablet); Ocaliva

Drug Summary

Global Status	Launched
Development Status	Active

Latest Change	PDUFA date as 26 Jun 2020 for non-alcoholic steatohepatitis reported
Latest Change Date	2020/01/20

the natural human bile acid CDCA (chenodeoxycholic acid), developed by Intercept
receptor (FxR) agonist for the treatment of primary biliary cirrhosis (PBC). It is also under
patitis (NASH) and primary sclerosing cholangitis (PSC) (Scrip Daily Online, 6 Sep 2004,
USAN Web Page, 5 Nov 2008; Press release, Intercept Pharmaceuticals, 8 Oct 2014,
=875121; Company pipeline, Sumitomo Dainippon Pharma, 29 Jan 2015, http://www.ds-

Disease / Company / Country

Show/Hide columns

Drug Disease	Company	Drug Country	Current Status	Launch Year	Preclinical	Phase I	Phase II	Phase III	Pre-reg.	Registered	Launched
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	USA	Launched	2016							
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Australia	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Austria	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Belgium	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Bulgaria	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Canada	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Croatia	Registered								
Cirrhosis, primary biliary	Intercept Pharmaceuticals (part of Genex tra)	Cyprus	Registered								

Chemical data

Origin	Chemical, synthetic
NCE	Yes
CAS registry number	459789-99-2
Molecular Formula	C26H44O4
Molecular Weight	420.63
logP	4.52

H Bond Donors	3
H Bond Acceptors	4
Rotatable Bonds	5
Chemical Name	(4R)-4-((3R,6R,7R,10S,13R)-6-e dimethylhexadecahydro-1H-cy yl)pentanoic acid
Chemical Structure (SMILES format)	CC[C@H](C[C@@H](O)C2C3CCC([[C@@]3(C)CCC2[C@@]2(C)CC[C

Chemical Structure



Trialtrove Trials

Trialtrove Trial Count 27

Phase	Disease	Sponsor	Drugs tested	Protocol/Trial ID	Status
I	Hepatic Fibrosis, NAFLD	Sumitomo Dainippon Pharma (Dainippon Sumitomo)	obeticholic acid	TrialTroveID-167308	Completed
I	Hepatic Fibrosis	Genextra/Intercept Pharmaceuticals	obeticholic acid	TrialTroveID-336296	Completed
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid (tablet)	TrialTroveID-245334; 747-104; NCT01914562	Completed
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	TrialTroveID-249887	Planned
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	TrialTroveID-186863	Completed
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	TrialTroveID-186989; 747-105; NCT01933503	Completed
II	NAFLD	Genextra/Intercept Pharmaceuticals	atorvastatin calcium; obeticholic acid	TrialTroveID-269972; 747-209; CONTROL; NCT02633956	Completed
II	Hepatic Fibrosis	Genextra/Intercept Pharmaceuticals	obeticholic acid	TrialTroveID-162443; 747-201; EudraCT Number: 2007-001424-12; ISRCTN68931598;	Completed

管线或药物数据 –可视化、编辑、导出

多元数据显示 – PDF/Excel导出

互动性图表显示



动态趋势显示



数据导出



Drug Trends by Global Status

Global Status	Number of Drug							
	2005	2006	2007	2008	2009	2010	2011	2012
Preclinical	100	90	97	131	117	136	125	96
Phase I Clinical Trial	44	40	84	75	78	74	81	59
Phase II Clinical Trial	40	55	76	73	56	66	68	72
Phase III Clinical Trial	24	20	15	24	23	27	37	28
Pre-registration	12	10	14	6	11	6	9	8
Registered	1	6	3	9	4	4	4	3
Launched	405	408	415	416	428	441	465	472
Suspended	3	1	2	4	3	2	1	3





Drug Trends by Global Status

Global Status	Number of Drug							
	2005	2006	2007	2008	2009	2010	2011	2012
Preclinical	100	90	97	131	117	136	125	96
Phase I Clinical Trial	44	40	84	75	78	74	81	59
Phase II Clinical Trial	40	55	76	73	56	66	68	72
Phase III Clinical Trial	24	20	15	24	23	27	37	28
Pre-registration	12	10	14	6	11	6	9	8
Registered	1	6	3	9	4	4		
Launched	405	408	415	416	428	441	46	
Suspended	3	1	2	4	3	2		



Pharma Intelligence
Informa

Citeline其他模块一览【未订阅】

Trialtrove – 全球临床试验信息
Sitetrove – 全球研究者及机构信息
Citeline Engage – 美国医师及患者真实世界数据

Pharma Intelligence
Informa

Trialtrove【未订阅】

全球临床试验信息

Trialtrove提供业界领先的临床试验信息，全面优化临床项目方案设计与管理以及降低风险与成本

Trialtrove 提供多方面支持

- 343,000+ 完整临床试验报告（一至四期）
- 43,000+ 公共领域引用来源
- 1,500+ 患者及疾病分类
- 1,000+ 临床终点
- 235+ 适应症
- 165+ 国家或地区

内容均由分析师团队手动查证及编制，
并与Pharmaprojects临床药物数据相互连接

临床试验竞争格局

通过了解全球竞争格局与个别竞争对手临床项目设计方案及时间表，提前预测潜在挑战

临床项目方案优化及有效管理

通过分析临床设计、临床终点及以往结果趋势，以及识别以往成功或失败案例以了解其中关键因素，最终最大化提高自身方案成功率

临床可行性及用时评估

详细分析临床用时、入组指标、项目管理、患者募集条件、国家选择、综合竞争格局等关键信息，最大限度作出最佳设计及选址决策

点击查阅Trialtrove疾病涵盖说明 & 综合内容涵盖说明

Pharma Intelligence
Informa

Sitetrove【未订阅】

全球临床研究者及机构信息

快速并有效完成临床项目策划及执行

Sitetrove云集全球超过180个国家或地区，约47万名一线临床研究者及17万个临床机构，涵盖范围持续增加中…

Sitetrove 提供多方面支持

Sitetrove研究者涵盖内容

- “分级排行功能”（Investigator Prioritization）
- 往年或当前临床经历
- 医学专长
- 联系方式
- FDA视察或监管部门记录
- 临近医生及患者数量
- 高级数据索引

Sitetrove临床研究者全球分布图



潜在研究者选择

根据实际临床项目需求、20亿条美国医保记录而成的患者群体数据，以及Sitetrove独有的研究者“分级排行功能”，快速识别出最佳人选

筹备美国患者转介网络

锁定美国潜在研究者人选，并掌握其25-250英里半径范围内专科医生人数及可用患者，更可进一步为建立患者转介网络奠定基础以便提高患者募集能力

临床项目选址

通过分析个别临床机构以往临床经历、当前参与项目程度及相应方案设计与进展，以及关联研究者，全面掌握当前临床竞争格局及选出最佳试验地点

内容均由分析师团队手动查证及编制，并与Trialtrove临床试验数据相互连接

点击查阅Sitetrove疾病涵盖说明 & 内容涵盖说明

Pharma Intelligence
Informa

Citeline Engage【未订阅】

美国医师及患者真实世界数据

业界挑战

临床试验设计复杂化、患者募集、研究者及选址竞争日渐激烈，更是导致业界临床项目用时及成本持续上涨的关键因素…

患者募集竞争格局

- 一项针对905个已终止临床项目的研究表明，其中38.7%（350）由于**缺乏足够患者**而被终止研究[1]
- 在特定疾病领域及临床程序数量之后，**入组速度缓慢是临床试验首要高成本原因**[2]

临床项目复杂性

- 一项历时十年并针对三期临床项目设计的趋势研究表明[3]:
  - 2x more countries
  - 63% more sites
  - 86% more endpoints
  - 18% less patients
- 其中**57%的临床项目**在研究期间出现临床项目调整[4]

时间与成本

- 单项平均药品临床研发总成本高达**10亿美元：**



- 选址至实际开展的平均用时则达**31.4个月** – 对比十年前平均上升一个月[5]

关键问题

- **高成本**
- **耗时**
- **复杂性**
- **竞争激烈**
- **入组速度缓慢**

Sources:
1. https://www.ncbi.nlm.nih.gov/pubmed/26908540
2. https://www.ncbi.nlm.nih.gov/pubmed/26011295
3. https://www.clinicalleader.com/doc/rising-protocol-complexity-is-hindering-performance-while-driving-study-of-drug-development-0001
4. https://www.centerwatch.com/news-online/2016/04/01/facing-protocol-amendments-head/
5. https://www.globenewswire.com/news-release/2018/03/07/1417625/0/en/First-Comprehensive-Clinical-Site-Initiation-Benchmark-Developed-by-Tufts-Center-for-the-Study-of-Drug-Development-Finds-Study-Startup-Is-Lengthy-and-Inefficient.html

业界挑战

传统患者募集方式逐渐失效…

关键因素：大量患者与医生对临床试验缺乏认知与相关资讯

关键挑战（患者）

- CISCRP于2017年针对12.4万名患者的一项调查以了解患者对临床试验的认知程度[1]
- 患者如何获悉临床试验资讯：
  - **主治医生（19%）**
  - **临床项目人员（17.6%）**
  - **广告或宣传用品（15.9%）**
- **44%**称临床试验**极少被视为实际选项或考虑方向**
- **94.3%**认为**医生时刻知晓临床试验是极为重要**

关键挑战（医生）

- Tufts CSDD的一项针对2000名护士与医生的调查证实，担心病人流失不是临床试验引荐量低下的原因[2]：
  - **90%医生**乐意向患者推荐相应临床试验
  - **仅9%医生**表示**担心病人流失**是导致决定不推荐临床试验的一大因素
- 由于对临床试验**缺乏所须资讯或认知**[3]，专业医疗人士仅向小部分患者推荐临床试验

结果

- 愿意或可参加临床试验**患者人数**低下，**目前人数**更无法满足日益增长的市场需求[4]
- 许多临床项目因患者募集困难而选择提前**终止**研究[5,6,7]
- **为了实现募集目标，申办方及CRO机构必须扩大医生及患者范围**





Sources:
1. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2705849
2. http://www.appliedclinicaltrialsonline.com/tufts-csdd-study-says-low-recruitment-rates-due-poor-engagement
3. https://www.clinicaltherapeutics.com/article/S0149-2918(17)30998-0/pdf
4. https://www.pharmacist.com/article/cancer-conundrum-too-many-drugs-too-few-patients
5. https://www.ncbi.nlm.nih.gov/pubmed/26908540
6. https://www.ncbi.nlm.nih.gov/pubmed/26011295
7. https://go.forteresearch.com/patient-recruitment-in-clinical-trials-steps-for-successful-strategy

解决方案【1】– 数据整合 *(免费)*

通过推出Citeline Engage服务， Sitetrove原有的美国研究者数据将进一步优化并实时配置超过88万名美国执业医生信息（如：专业、距离研究者范围、患者人数等）[1,2]

Sitetrove新扩展功能

1. 识别资深美国研究者，并掌握邻近各地医生与患者人数（根据以往两年诊断与医保记录）
2. 根据疾病进行筛选以便找出特定领域内拥有最多医生及可用患者人数群体的研究者名单
3. 掌握特定研究者或机构邻近的医生及患者人数
4. 使用原有研究者分级功能（Investigator Prioritization）并进一步结合真实世界数据筛选出拥有最多邻近医生或患者人数的研究者

远超Sitetrove涵盖范围，Citeline Engage共涵盖170万名美国医疗专业人士信息，以便涵盖全新或罕见疾病

Sitetrove数据强化

- 基于真实世界数据，进一步优化临床可行性分析与研究者/地点选址
- 原有数据免费强化



Notes:
1. At no additional cost to Sitetrove customers!
2. Physician contact information/full profiles *will not* be included in Sitetrove. This information is only accessible through Citeline Engage outreach services. The new Sitetrove data includes US physician counts, physician specialties, physician proximity to known Sitetrove clinical investigators, and patient availability

解决方案【2】– Engage服务 *（收费）*

Engage服务将提供三大服务支持[1]

1 Use Case: Recruit

- 通过直接接触关键患者群体并优化**患者募集以及资深或新研究者人选**
- **如何做到？** 将配置一名Citelinte Engage专业临床研究专员，并共同规划及执行订制方案
- **Service names**: Recruit Investigators

2 Use Case: Optimize

- 根据实时专家反馈进一步优化**临床设计**
- **如何做到？** 通过组织专家反馈会议，实时获取资深执业医生或业界权威（KOLs）的独家建议
- **Service name:** Gather

3 Use Case: Ignite

- 通过Citeline Engage网络向特定医生或医疗业者**提高临床试验资讯与关注度**
- **如何做到？** 通过订制邮件、赞助广告、或特定宣传内容，无限提高社区网络中临床项目关注度
- **Service names**: Skoop, Trial Sponsorship

通过Engage服务您将获取共88万名执业医生与170万医疗从业者的关系网络

Notes:
1. We welcome the opportunity to explore additional use cases of interest

Pharma Intelligence
Informa

Citeline主要综合功能

逻辑检索、数据显示、数据追踪

Citeline线上统一平台界面
（各产品拥有相同设计）



视觉逻辑检索（Visual Boolean Search）
逻辑思维连接

动态多元检索

- ✓ 凭直觉搭建复杂检索
- ✓ 数据随检索同步更新
- ✓ 查阅筛选经过并适当作出调整

方便修改
注重逻辑连接

- ✓ 调整各关键词筛选用途（is, is not, is only, contains, does not contain）
- ✓ 随意拖动搭配筛选条件，组成合理逻辑思维连接
- ✓ 修改连接词（and/or），构建复杂检索



数据可视化 (Data Visualization)
多元数据显示 – PDF/Excel导出

Pharmaprojects
Informa Pharma Intelligence



Trialtrove
Informa Pharma Intelligence



Sitetrove
Informa Pharma Intelligence



Citeline Engage
Informa Pharma Intelligence









Notes:
1. Pharmaprojects' 'Phase Advancement Chart' display currently available online only
2. 'Map' display currently available online only, can be used via screenshot
3. Further enhancement may be applied based on client feedback

数据追踪（Alerts）
时刻追踪市场变化 – 邮件接收或线上追踪

实时追踪
业界或竞争对手动态

- ✓ 针对完整检索或个别药物、临床试验、研究者或机构设置Alert
- ✓ 实时关注业界创新药物、全新临床项目及研究者或机构
- ✓ 自动获悉事件更新，掌控市场动态

个性化设置

- ✓ 针对特定事件类型设置追踪
- ✓ 预先设置更新频率
- ✓ 通过邮件接收或线上追踪，实时掌握市场更新



Pharma Intelligence
Informa

分析师咨询服务
Ask the Analyst™

业界专家一对一辅助

通过Ask-the-Analyst服务与超过250名分析师直接连线

每提问三小时调研时间
无须额外费用…

专业解答

为订阅者独家提供可行的个性化咨询服务，其中包括订制的数据收集及调研支持

高效答复

24小时内回复（额外调研除外）
通过透明及可查证的信息来源，提供完整解答以便作出正确决策

跨产品调研支持

引用其他订阅产品提供完整数据辅助
Platinum级别客户则可享全产品调研支持

拥有超过250名高资历（硕士及博士学位）并充分了解您独特需求的资深专家团队...

Got a question?
Ask the Analyst™

通过Ask-the-Analyst服务与超过250名分析师直接连线

每提问三小时调研时间

无须额外费用…

难题待解?

直接点击“Ask the Analyst”按钮向分析师团队进行提问!

您将获得针对您具体需求的**一对一分析师咨询支持** – 分析师团队每天负责对所有信息进行整编、验证及分析，并向您提供所需帮助。



以往提问例子…

Pharmaprojects

“能否总结一下所有创伤后应激障碍（PTSD）领域被终止研发的原因？（如：xx %缺乏研发进展、xx %无任何后续报道等）另外，我想了解GSK、Biomics及辉瑞在该领域终止研发的原因。”

Trialtrove

“我需要该项名为STEADY-PD III (NCT02168842)帕金森病临床研究的资讯，麻烦提供任何有关入组、患者保留方案或各期临床数据披露。”

Sitetrove

“我需要寻找拥有使用小瓶或注射器进行1型糖尿病临床试验经验的合适研究者人选，目标国家为：保加利亚、印度、马来西亚、菲律宾、俄罗斯以及美国，不知能否提供帮助？”

Citeline Engage

“我正进行一项复杂的可行性评估，并需要下列辅助：竞争格局、基准数据、研究者及机构信息、以及Citeline Engage附加服务下有关可开刀恶性乳腺癌的专家反馈。我的临床项目主要关注初次切除后成像，因此需要常驻美国的乳腺癌领域或外科肿瘤专家。”

Pharma Intelligence
Informa

使用案例【1】– 综合格局分析

Pharmaprojects – 临床药物

Trialtrove – 临床试验

Sitetrove – 研究者及机构

Citeline Engage – 全美医师及患者数据

调研案例

银屑病（Psoriasis）– Search, Analyze, Benchmark

Pharmaprojects – Clinical Drugs

a) 如何检索当前在研管线及竞争格局（如：公司、所用靶点等）？ Search Available

b) 比照药物何时、何地获批上市，并找出所有相应临床试验？Search Available

c) 如何查询全球tyrosine kinase 2靶点的历史研发趋势，并导出各年份药物列表？ Search Available

d) 如何查询拥有孤儿药或快速审评状态的在研抗银屑病药物，并了解其进展？ Search Available

e) 如何查询正寻找合作伙伴（中国）的抗银屑病在研药物？ Search Available

注：目前仅订阅Pharmaprojects

Trialtrove/Trialpredict – Clinical Trials plus Historical Benchmarking

a) 如何检索当前全球范围内正在进行中或即将开始，并由药企资助的临床二期银屑病研究？谁是竞争对手，其最新进展为如何？ Search Available

b) 如何检索出由药企资助的已完成临床二期银屑病研究？ Search Available
其成功及失败因素是什么？ Positive Outcome vs. Negative Outcome

c) 如何分析以往成功项目的关键数据（如：入组速度、募集人数及地点选择、每月平均募集人数等）？ Search Available

Sitetrove/Citeline Engage – Investigators/Sites plus US Physician/Patient Pool Data (based on real-world data)

a) 如何找出拥有临床二期银屑病研究经历并近期无监管警告的最佳研究者（Tier-1），
了解其当前所在地、联系方式、以往经历，以及当前是否有进行其他研究？ Search Available

b) 如何找出拥有临床二期银屑病研究经历的研究机构，其中有多少是在美国境内？ Search Available

c) 如何通过Citeline Engage真实世界数据，了解当前全美注册医师及患者群体分布，并从Tier-1研究者人选中作进一步筛选？ Search Available

注：检索数据均取自2020年4月

Case Study – Pharmaprojects

1、如何检索当前在研管线及竞争格局（如：公司、所用靶点等）？ Search Available













Notes:

***'Most Advanced Current Status'* Filter:**

- Returns drugs where the most advanced of its 'Current Statuses' is at the status selected.
- Combine with a disease, company or country to return drugs where the most advanced status for that disease, company or country is at the status selected.
- For more information see here.

Case Study – Pharmaprojects

2、比照药物何时何地获批上市，并找出所有相应临床试验？ Drug Profile Available

Drug

- Drug Summary
- Chemical data
- Activity
- Trialtrove Trials
- Disease / Company / Country
- Partnering Availability
- Event History
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

risankizumab

ABBV 066; ABBV-066; ABBV066; BI 655066; BI 655066 (IV); BI 655066 (SC); BI-655066; BI-655066 (IV); BI-655066 (SC); BI655066; risankizumab; risankizumab (IV); risankizumab (SC); Skyrizi

Drug Summary

Global Status	Launched
Development Status	Active

Latest Change	Expected timing of regulatory filing for psoriatic arthritis in 2021 reported
Latest Change Date	2020/02/12

Drug Disease	Company	Drug Country	Launch Year	Preclinical	Phase I	Phase II	Phase III	Pre-reg.	Registered	Launched
Arthritis, psoriatic	AbbVie	Japan	2019							
Psoriasis	AbbVie	Japan	2019							
Psoriasis	AbbVie	USA								
Psoriasis	AbbVie	Australia								
Psoriasis										
Psoriasis										
Psoriasis										
Psoriasis										

Approvals

Psoriasis: Arthritis psoriatic
Japan (2019); as Skyrizi for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies (Press release, AbbVie, 26 Mar 2019, https://news.abbvie.com/news/press-releases/abbvie-announces-first-regulato...; Press release, Abbvie, 24 May 2019, https://www.abbvie.co.jp/content/dam/abbvie-dotcom/jp/documents/press-relea...).

Psoriasis
Australia; as Skyrizi for the treatment of psoriasis aged 18 yr or older who are candidates for phototherapy or systemic therapy (Press release, TGA Web Page, 12 Aug 2019, https://www.tga.gov.au/prescription-medicines-registration-new-chemical-ent...).
Brazil; as Skyrizi for the treatment of psoriasis in adults (Scrip Intelligence, 3 Jun 2019, https://scrip.pharmaintelligence.informa.com/SC125315/Pipeline-Watch-Phase-...).
Canada; as Skyrizi for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (Press release, AbbVie, 18 Apr 2019, http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/SKYRIZI_Final_press_...).
EU including Iceland, Liechtenstein and Norway; as Skyrizi for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy (Press release, AbbVie, 23 Apr 2019, https://news.abbvie.com/news/press-releases/abbvie-expands-immunology-portf...; Press release, AbbVie, 30 Apr 2019, https://news.abbvie.com/news/press-releases/european-commission-approves-sk...).
USA (2019); as Skyrizi for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (Scrip Intelligence, 28 Oct 2017, https://scrip.pharmaintelligence.informa.com/SC099770/New-AbbVie-Guidance-S...; Pink Sheet Intelligence, 26 Feb 2019, https://pink.pharmaintelligence.informa.com/PS124822/Risankizumab-Andexanet...; Press release, AbbVie, 23 Apr 2019, https://news.abbvie.com/news/press-releases/abbvie-expands-immunology-portf...; Form 10-Q, AbbVie, 5 Aug 2019, Page 25,https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000155115219000023/...).

Case Study – Pharmaprojects

2、比照药物何时何地获批上市，并找出所有相应临床试验？ Drug Profile Available

Drug

- Drug Summary
- Chemical data
- Activity
- Trialtrove Trials
- Disease / Company / Country
- Partnering Availability
- Event History
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

Trialtrove Trials

注：Trialtrove须额外使用权限

Trialtrove Trial Count: 39

Phase	Disease	Sponsor	Drugs tested	Protocol/Trial ID	Status
IV	Psoriasis	AbbVie	risankizumab; undisclosed - biologic	TrialTroveID-351313; NCT03982394; P19-377; VALUE	Open
III	Crohn's Disease	AbbVie	risankizumab (IV); risankizumab (SC)	TrialTroveID-298925; 18-ABV-02; EudraCT Number: 2016-003190-17; M15-991; NCT03104413; NL60378.018.17; NMRR-17-1305-36321	Open
III	Other Inflammatory Arthritis	Boehringer Ingelheim, AbbVie	risankizumab	TrialTroveID-262918; EudraCT Number: 2017-002464-40; IMMpact2; M15-998; NCT03671148; NL67817.078.18	Closed
III	Psoriasis	AbbVie	risankizumab (SC)	TrialTroveID-323905; IMMPRESS; M16-176; NCT03518047	Completed





Case Study – Pharmaprojects

3、如何查询全球tyrosine kinase 2靶点的历史研发趋势，并导出各年份药物列表？Search Available

24 drugs
View related: Trials (80) | Investigators (531) | Organizations (1,156)

Target is tyrosine kinase 2

Export

Development Status | Global Status

Export options
Export all charts and tables
Export underlying historical data
Your export may take a few moments to process. Thank you for your patience.
Cancel Continue

B	C	D	E
Generic Drug Name	Drug Names	Trends year	Global Status
TD-EyeJAKi	TD EyeJAKi; TDEyeJAKi; TD-EyeJAKi	2019	Preclinical
ABBV-712	ABBV 712; ABBV712; ABBV-712	2019	Phase I Clinical Trial
TYK2 inhibitors, Nuevolution	TYK2 inhibitors, Nuevolution	2019	Preclinical
SDC-1802	SDC 1802; SDC1802; SDC-1802	2019	Preclinical
SDC-1801	SDC 1801; SDC1801; SDC-1801	2019	Preclinical
TD-8236	JAK inhibitor, Theravance Biopharma; TD 8236; TD	2019	Phase I Clinical Trial
GLPG-3121	GLPG 3121; GLPG3121; GLPG-3121	2019	Phase I Clinical Trial
PF-06826647	PF 06826647; PF 6826647; PF06826647; PF-	2019	Phase I Clinical Trial



Case Study – Pharmaprojects

4、如何查询拥有孤儿药或快速审评状态的在研抗银屑病药物，并了解其进展？Search Available



Generic Drug Name	Company	Originator / Licensee	Drug Disease	Drug Country	Preclinical	Phase I	Phase II	Phase III	Pre-reg.	Registered	Launched
adalimumab, Henlius	Shanghai Henlius Biotech	Originator	Uveitis	China							
	Shanghai Henlius Biotech	Originator	Spondyloarthritis, axial	China							
	Shanghai Henlius Biotech	Originator	Psoriasis	China							
	Shanghai Henlius Biotech	Originator	Hidradenitis suppurativa	China							
	Shanghai Henlius Biotech	Originator	Crohn's disease	China							
	Shanghai Henlius Biotech	Originator	Colitis, ulcerative	China							
	Shanghai Henlius Biotech	Originator	Arthritis, rheumatoid	China							
	Shanghai Henlius Biotech	Originator	Arthritis, psoriatic	China							
	Shanghai Henlius Biotech	Originator	Arthritis, juvenile	China							
	Shanghai Henlius Biotech	Originator	Ankylosing spondylitis	China							
	show less										
adalimumab, Innovent Biologics	Innovent Biologics	Originator	Uveitis	China							
	Innovent Biologics	Originator	Spondyloarthritis, axial	China							
	Innovent Biologics	Originator	Psoriasis	China							
	Innovent Biologics	Originator	Hidradenitis suppurativa	China							
	Innovent Biologics	Originator	Crohn's disease	China							
	Innovent Biologics	Originator	Colitis, ulcerative	China							
	Innovent Biologics	Originator	Arthritis, rheumatoid	China							
	Innovent Biologics	Originator	Arthritis, psoriatic	China							
	Innovent Biologics	Originator	Arthritis, juvenile	China							
	Innovent Biologics	Originator	Ankylosing spondylitis	China							
	show less										

Generic Drug Name	Marketing	Licensing	Phase III	Phase II	Phase I
adalimumab, Henlius	Approvals _____ Unspecified China; launch is planned between 2018-2020 (Company presentation, Henlius, 9 Jan 2016, Slide 7 & 17, ...		Psoriasis It is in a randomized, double-blind, parallel-group Phase III trial (HLX03-Ps03) in 216 patients with moderate-to-severe plaque psoriasis in China, to evaluate the efficacy, safety, tolerability and immunogenicity of HLX-03 sc versus ...		It is in a randomized, double-blind, parallel-assignment, controlled, single-dose Phase I trial (HLX03-HV01; CTR20160930) in 148 chinese healthy male subjects, to evaluate the pharmacokinetics, safety, tolerability and immunogenicity of HLX-03 sc ...
adalimumab, Innovent Biologics	Filings _____ s; Arthritis, an NDA for spondylitis A) and psor review by NMPA in Nov 2018 (Press release, ...		Ankylosing spondylitis A pivotal, randomized, double-blind, active controlled, parallel, head-to-head, pharmacokinetics and bioequivalence comparability Phase III trial (CIBI303A301) in 438 patients wih ankylosing spondylitis in China, to evaluate ...		In an exploratory healthy volunteers study, it was demonstrated to be safe (Press release, Innovent Biologics, 13 Sep 2016, http://www.innoventbio.com/en/News.aspx?key=news&Id=1361&type=%E6%96%B0%E9%...).

Filings _____ Ankylosing spondylitis; Arthritis, rheumatoid, Psoriasis China; an NDA for the treatment of ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis has been accepted for review by NMPA in Nov 2018 (Press release, Innovent Biologics, 12 Nov 2018, https://www.prnewswire.com/news-releases/nmpa-accepts-biosimilar-new-drug-a...). Expedited Review Designation _____ Ankylosing spondylitis; Arthritis, rheumatoid, Psoriasis China; It has received priority review status (Press release, Innovent Biologics, 27 Jun 2019, http://innoventbio.com/en/#/news/151).

Notes:

***'Most Advanced Current Status'* Filter:**

- Returns drugs where the most advanced of its 'Current Statuses' is at the status selected.
- Combine with a disease, company or country to return drugs where the most advanced status for that disease, company or country is at the status selected.
- For more information see here.

回到目录页面

Case Study – Pharmaprojects

4、如何查询拥有孤儿药或快速审评状态的在研抗银屑病药物，并了解其进展？Drug Profile Available

Drug

- Drug Summary
- Chemical data
- Activity
- Trialtrove Trials
- Disease / Company / Country
- Partnering Availability
- Event History
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

adalimumab, Innovent Biologics

adalimumab, Innovent Biologics; IBI 303; IBI-303; IBI303

Drug Summary

Global Status	Pre-registration
Development Status	Active

Latest Change	Top-line results of Phase III trial (CIBI303A301) for ankylosing spondylitis reported
Latest Change Date	2019/09/18

Event History

Date	Status	Description
2019/06/27	Expedited Review Designation Granted	China; Ankylosing spondylitis; Arthritis, rheumatoid, Psoriasis
2018/11/12	First Filing	China; Ankylosing spondylitis, Arthritis, rheumatoid, Psoriasis
2016/09/13	Global Status Advance	Phase III Clinical Trial
2013/10/16	New Therapeutic Class	Antipsoriasis
2013/10/16	New Therapeutic Class	GI inflammatory/bowel disorders
2013/10/16	New Disease	Arthritis, psoriatic
2013/10/16	New Disease	Crohn's disease
2013/10/16	New Disease	
2011/10/19	Drug Added	

Marketing

Filings

Ankylosing spondylitis; Arthritis, rheumatoid, Psoriasis
China; an NDA for the treatment of ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis has been accepted for review by NMPA in Nov 2018 (Press release, Innovent Biologics, 12 Nov 2018, https://www.prnewswire.com/news-releases/nmpa-accepts-biosimilar-new-drug-a...).

Expedited Review Designation

Ankylosing spondylitis; Arthritis, rheumatoid, Psoriasis
China; It has received priority review status (Press release, Innovent Biologics, 27 Jun 2019, http://innoventbio.com/en/#/news/151).

Case Study – Pharmaprojects

5、如何查询正寻找合作伙伴（中国）的抗银屑病在研药物？Search Available



Generic Drug Name	Company	Originator / Licensee	Drug Disease	Drug Country	Preclinical	Phase I	Phase II	Phase III	Pre-reg.	Registered	Launched
adalimumab, Gene Techno Science	Gene Techno Science	Originator	Psoriasis	Japan							
	show more										
adalimumab, Mycenax	Mycenax	Originator	Psoriasis	Taiwan							
	show more										
alicaforsen	Aspen Pharmacare Holdings	Licensee	Psoriasis	Australia							
	show more										
AUR-101	Dr. Reddy's Laboratories	Originator	Psoriasis	India							
belapectin	Galectin Therapeutics	Originator	Psoriasis	USA							
	show more										
BOS-173717	Boston Pharmaceuticals	Originator	Psoriasis	USA							
	show more										
calcipotriol, Lipidor	Cerbios-Pharma	Licensee	Psoriasis	Switzerland							
	Lipidor	Originator	Psoriasis	Sweden							
	Lipidor	Originator	Psoriasis	Germany							
	Cadila Pharmaceuticals	Licensee	Psoriasis	India							
	Cerbios-Pharma	Licensee	Psoriasis	India							
	Lipidor	Originator	Psoriasis	India							







Notes:

***'Most Advanced Current Status'* Filter:**

- Returns drugs where the most advanced of its 'Current Statuses' is at the status selected.
- Combine with a disease, company or country to return drugs where the most advanced status for that disease, company or country is at the status selected.
- For more information see here.

Note:

1. **"Partnership Availability"** tool mines through all publicly disclosed information with credible sources available via URL links.
2. Please also feel free to add in the filter of "*Partnering Availability: Country is Undisclosed*", as some potential candidates may be open for partnership agreement upon contact.

Case Study – Pharmaprojects

5、如何查询正寻找合作伙伴（中国）的抗银屑病在研药物？Drug Profile Available

Drug

AUR-101

AUR 101; AUR-101; AUR101; ROR inverse agonist, Aurigene Discovery Technologies

- **Drug Summary**
- Chemical data
- Activity
- Trialtrove Trials
- Disease / Company / Country
- Partnering Availability
- Event History
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

Drug Summary

Global Status	Phase II Clinical Trial	Latest Change	Dosing of Phase II trial for psoriasis and route as po reported
Development Status	Active	Latest Change Date	2020/02/21

Partnering Availability

Country	Available to Partner
Chile	Yes
Austria	Yes
Canada	Yes
Brazil	Yes
Belgium	Yes
Australia	Yes
Argentina	Yes
China	Yes
Colombia	Yes

Licensing

Availability

Worldwide; available for co-development (Company web page, Aurigene, 28 Jun 2017, http://www.aurigene.com/proprietary-programs/ & http://128.199.141.159/th17-pathway/).

Phase II

Psoriasis

It is in a randomized, double-blind, placebo-controlled, parallel-assignment Indian Phase II trial (INDUS-2; AUR101-201) in India in 90 subjects with moderate-to-severe psoriasis, to evaluate the efficacy and safety of two doses of AUR-101 400 and 600mg po. Dosing has been initiated (ClinicalTrials,gov, 23 Dec 2019, https://www.clinicaltrials.gov/ct2/show/NCT04207801; Company pipeline, Aurigene, 31 Dec 2019, https://www.aurigene.com/proprietary-programs-spin-out/; Press release, Aurigene, 17 Feb 2020, https://www.aurigene.com/aurigene-announces-first-patient-dosed-with-aur101...).

Phase I

A Phase I (INDUS) trial in healthy volunteers to evaluate the safety signals, pharmacodynamic modulation, and recommended dosage for Phase II studies (RP2D) is complete (Company Web Page, Aurigene, 12 Jul 2018; Company pipeline, Aurigene, 12 Jul 2018; Press release, Aurigene, 11 Jul 2018, https://www.prnewswire.com/news-releases/aurigene-announces-first-in-human-...; Company pipeline, Aurigene, 1 Feb 2019 & 16 Jul 2019, https://www.aurigene.com/proprietary-programs-spin-out/).

A Phase I trial to evaluate AUR-101 in Australia, is complete (Press release, Aurigene, 17 Feb 2020, https://www.aurigene.com/aurigene-announces-first-patient-dosed-with-aur101...).

Note:

1. **"Partnership Availability"** tool mines through all publicly disclosed information with credible sources available via URL links.
2. Please also feel free to add in the filter of "*Partnering Availability: Country is Undisclosed*", as some potential candidates may be open for partnership agreement upon contact.

Pharma Intelligence
Informa

使用案例【2】– 业界动态追踪

Pharmaprojects – 临床药物

Trialtrove – 临床试验

Sitetrove – 研究者及机构

Citeline Engage – 全美医师及患者数据

Alerts设置 – 实时追踪业界动态

检索范围 vs. 个别项目【药物、临床试验、研究者、临床机构或中心】

例：COVID-19全球管线 A



B 例：瑞德西韦【吉利德】



邮件接收 + 线上记录





回到目录页面

Alerts范例

直接点击开启订阅或通过Ask-the-Analyst免费寻求辅助

例：乳腺癌（Breast Cancer）

- ❑ **Pharmaprojects (药物信息)**
  - 在12个月内有进展的临床二期抗乳癌药物 vs. 12个月内未有进展的药物
  - 在亚太主要国家或地区研发并处于二期抗乳癌生物药管线
  - 由原研公司为中国药企的所有抗乳癌生物药（不限临床阶段或状态）

  注：目前仅订阅Pharmaprojects

- ❑ **Trialtrove (临床试验信息)**
  - 由药企资助的全球乳癌临床试验及当前竞争格局（仅限进行中或计划启动的项目）
  - 由药企资助的全球HER2+乳癌二期临床历史成功项目 vs. 失败项目
  - 因COVID-19而受影响（如：入组/项目延误等）的全球乳癌临床试验项目 vs. 因COVID-19而宣布暂停或终止的乳癌临床试验项目

- ❑ **Sitetrove (研究者及临床机构信息)**
  - 拥有乳癌临床经历（含：已完成、进行中、计划启动）的全球研究者 vs. 全球研究机构/中心
  - 当前正参与由药企资助并已完成入组的三阴乳癌二期临床试验项目的全球研究者 vs. 全球临床机构/中心
  - 美国乳癌领域研究者、医师、患者群体真实世界数据（注：患者数据基于以往两年全美联邦[100%]及商业[80%]医保记录）

需要辅助搭建特定检索或设置Alerts? *Ask-the-Analyst!*



以往用户提问：

- ❖ *"能否同时针对多个国内外药企的早期管线设置自动邮件追踪，但每天只接收一封邮件并能概括所有最新进展（若有更新）？"*
- ❖ *"我需要时刻掌握罕见病领域全球研发管线的当前竞争格局以及最新动态，特别是需要第一时间获悉新进场的药企或相关项目，不知应如何检索及设置追踪？"*
- ❖ *"如何搜出所有近两年由药企资助并已完成入组的NASH多国多中心临床试验项目？"*
- ❖ *"不知如何检索当前所有溶瘤病毒+抗癌药联用的临床试验，以及如何查阅已完成入组或已完成的相关项目并了解其平均入组人数与用时以及启用的临床中心？"*
- ❖ *"由于今年新冠病毒疫情来袭，我方想持续追踪所有因疫情而受影响（如：延后或终止）的癌症临床研究项目以便用于前景评估，不知能否有效检索及设置追踪？"*
- ❖ *"我司需要全球范围拥有HER2+乳癌临床经历并在近两年有参与临床项目的Tier-1研究者以及临床机构列表，除了基本资讯以外希望能提供完整的相关临床经历信息（如：已完成/正参与/即将启动的临床项目数量、相关参与项目的申办方等）？"*

Pharma Intelligence
Informa

客户支持

全球或区内客服

全球免费公开培训

每月各时区基础或特定领域公开培训【英语、日语、中文】
点击查阅并注册



回到目录页面

关键辅助链接 – Citeline Help Center (点击查阅)

- **各产品涵盖范围**
  - Trialtrove & Sitetrove疾病涵盖说明 – https://citeline.zendesk.com/hc/en-us/categories/360000327534-Trialtrove-and-Sitetrove-Disease-Scope-Statements
  - Pharmaprojects内容涵盖说明 – https://citeline.zendesk.com/hc/en-us/articles/360007579834-Pharmaprojects-Scope-Statement
- **用词释义**
  - Trialtrove & Sitetrove Study Keyword释义 – https://citeline.zendesk.com/hc/en-us/articles/360017923593-Trialtrove-Sitetrove-Study-Keyword-Definitions
  - Trialtrove & Trialpredict Category释义 – https://citeline.zendesk.com/hc/en-us/articles/360006300933-Trialtrove-Trialpredict-Sitetrove-Glossary-Category-Definitions-
  - Pharmaprojects用词释义（一般）– https://citeline.zendesk.com/hc/en-us/articles/360008401514-Pharmaprojects-Glossary-General
  - Pharmaprojects事件一览及释义 – https://citeline.zendesk.com/hc/en-us/articles/360008402554-Pharmaprojects-Glossary-Drug-Events
- **关键功能教程**
  - Citeline基础使用 – https://citeline.zendesk.com/hc/en-us/sections/360000990334-General-Citeline-Functionality
  - Sitetrove – https://citeline.zendesk.com/hc/en-us/sections/360000819674-Sitetrove
  - Pharmaprojects – https://citeline.zendesk.com/hc/en-us/sections/360000990354-Pharmaprojects
  - Trialpredict – https://citeline.zendesk.com/hc/en-us/sections/360000819854-Trialpredict-Trial-Timing-Data
  - Investigator Prioritization – https://citeline.informa.com/investigators/column-info/investigatorDiseaseTier
  - Citeline Engage – https://citeline.zendesk.com/hc/en-us/categories/360000285753-Citeline-Engage
- **分析师提示**
  - Trialtrove – https://citeline.zendesk.com/hc/en-us/sections/360002365814-Trialtrove-Analyst-Tips
  - Sitetrove – https://citeline.zendesk.com/hc/en-us/sections/360002387573-Sitetrove-Analyst-Tips
  - Pharmaprojects – https://citeline.zendesk.com/hc/en-us/sections/360002365854-Pharmaprojects-Analyst-Tips
- **线上教程视频**
  - Trialtrove基础教程 – https://citeline.zendesk.com/hc/en-us/articles/360007613553-Welcome-to-Trialtrove-recorded-training-link-July-2018-10-minutes
  - Sitetrove基础教程 – https://citeline.zendesk.com/hc/en-us/articles/360007513034-Welcome-to-Sitetrove-recorded-training-link-July-2018-9-minutes
  - Pharmaprojects基础教程 – https://citeline.zendesk.com/hc/en-us/articles/360005354894-Welcome-to-Pharmaprojects-demo-5-minutes
  - 自动邮件提醒设置 – https://citeline.zendesk.com/hc/en-us/articles/360006039174-Watches-and-Alerts-recorded-link
  - Citeline临床调研及可行性评估 – https://citeline.zendesk.com/hc/en-us/articles/360015534754-Using-Citeline-for-Clinical-Operations-and-Feasibility-recorded-training-link-29-Min

回到目录页面

Pharma Intelligence
Informa

联系我们

电话（美国）： +1 888 670 8900
电话（英国及欧洲）： +44 (20) 377 73737
电话（澳大利亚）： +61 2 8705 6907
电话（日本）： +81 3 6273 4260

客服邮箱：clientservices@pharmaintel.informa.com（全球）
官方网站：pharmaintelligence.informa.com